The slip
PARKINSON RECEIPTno. 2679
19 Oct 2026, 02:47 UTCdopamine neurons, braak
predictionSGCE in dopamine neurons tracks Braak Lewy-body stage
registered5aaa22b12681666a
discovery+0.63 p=0.067 n=9
replication-0.20 p=0.613 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.63, p 0.067)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTe1acdb64d701e1be2c87702d…
follows 8849a730b268…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 2679: SGCE in dopamine neurons, braak
- power
- full sample +0.23 (p 0.355, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.332, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.254, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.38, sign flips 0; without severely affected donors +0.23 (p 0.355, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.71 (p 0.0011, n 18) vs +0.23 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SGCE in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SGCE · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.13 p 0.657 (needs p < 6.8e-4)